Newly identified adverse events for gemcitabine using the Food and Drug Administration Adverse Event Reporting System-Reference-Cited by-同舟云学术

登录注册会员服务联系我们

Newly identified adverse events for gemcitabine using the Food and Drug Administration Adverse Event Reporting System

Published:2023-11-16 Issue: Volume: Page:1-7
ISSN:1474-0338
Container-title:Expert Opinion on Drug Safety
language:en
Short-container-title:Expert Opinion on Drug Safety

Author:

Zhang Wei¹,Wang Yuhong²,Jiang Xin¹,Zhao Hu¹,Jia Xinli¹,Wang Qiye¹,Chen Yue¹,Jiang Yuanfang¹,Ma Zhifang¹,Chang Lina³,Wang Xin¹

Affiliation:

1. Department of Urology, First Hospital of Shanxi Medical University, Taiyuan, Shanxi, China

2. Shanxi Medical Service Evaluation Center, Department of health management, Taiyuan, Shanxi, China

3. Shanxi Provincial Hospital of Traditional Chinese Medicine, Department of Physician Standardization Training Center, Taiyuan, Shanxi, China

Funder

Shanxi Scholarship Council of China

Publisher

Informa UK Limited

Subject

Pharmacology (medical),General Medicine

Link

https://www.tandfonline.com/doi/pdf/10.1080/14740338.2023.2284989

Reference29 articles.

1. Synthesis of 2-deoxy-2,2-difluoro-D-ribose and 2-deoxy-2,2'-difluoro-D-ribofuranosyl nucleosides

2. Improvements in survival and clinical benefit with gemcitabine as first-line therapy for patients with advanced pancreas cancer: a randomized trial.

3. Gemcitabine: metabolism, mechanisms of action, and self-potentiation;Plunkett W;Semin Oncol,1995

4. A real-world data analysis of topotecan in the FDA adverse event Reporting system (FAERS) database;Yang H;Expert Opin Drug Metab Toxicol,2023

5. Gemcitabine-Induced Pulmonary Toxicity

同舟云学术

1.学者识别学者识别

2.学术分析学术分析

3.人才评估人才评估

"同舟云学术"是以全球学者为主线，采集、加工和组织学术论文而形成的新型学术文献查询和分析系统，可以对全球学者进行文献检索和人才价值评估。用户可以通过关注某些学科领域的顶尖人物而持续追踪该领域的学科进展和研究前沿。经过近期的数据扩容，当前同舟云学术共收录了国内外主流学术期刊6万余种，收集的期刊论文及会议论文总量共计约1.5亿篇，并以每天添加12000余篇中外论文的速度递增。我们也可以为用户提供个性化、定制化的学者数据。欢迎来电咨询！咨询电话：010-8811{复制后删除}0370

www.globalauthorid.com

TOP